Medscape November 8, 2023
WASHINGTON (Reuters) – The U.S. Federal Trade Commission (FTC) on Tuesday said it sent letters to medical device companies and drugmakers, including AbbVie, AstraZeneca and Teva, disputing the accuracy or relevance of 110 patents that could lead to delays in generic competition.
Many of the patents at issue in the Food and Drug Administration’s Orange Book listing of approved products were for devices such as asthma inhalers and epinephrine autoinjectors, the FTC said.
“Wrongfully listed Orange Book patents by pharma companies can raise drug prices for Americans, harm fair competition, and delay better drugs,” FTC Chair Lina Khan said on X, formerly known as Twitter.
“Millions of Americans rely on inhalers to control their asthma. And even though some of...
Today's Sponsors
Today's Sponsor